Revvityの空売り状況は、投資家がRevvityの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Revvity (NYSE:RVTY) 株価情報, 空売り情報

Revvity

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Revvity Inc

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 0.1% on Tuesday.
Shares of Acelyrin, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRN#NASDAQ">SLRN</a>) fell sharply in today's <a href="https://www.benzinga.com/quote/SLRN">pre-market trading</a>.
ACELYRIN announced additional Phase 2 data and the Phase 3 program design for lonigutamab in Thyroid Eye Disease.
Acelyrin shares tumbled 15.4% to $2.95 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Cogent Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) shares fell 13.2% to $7.00 in pre-market trading.</li>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) fell 12.2% to $10.55 in pre-market trading after jumping 32% on Monday.</li>
<li>Alpha Teknova, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) dipped 7.3% to $8.40 in pre-market trading following a 4% gain on Monday.</li>
<li>Third Harmonic Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) fell 6.8% to $10.41 in pre-market trading.</li>
<li>Y-mAbs Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) fell 3.7% to $7.52 in pre-market trading.</li>
<li>NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>) fell 4.8% to $11.36 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell 1.7% to $404.26 in pre-market trading. Tesla on Monday reminisced about delivering the first Model 3 cars made at the company's gigafactory in Shanghai.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

COGT

NPCE

SLRN

THRD

TKNO

TSLA

YMAB

Acelyrin, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

WIIM

PMEC

Primtech shares are trading higher after the company announced it secured over $3.8 million in contracts across several economic sectors.

Seasoned Executive to Lead Strategy Across Capital Markets, Partner and Customer Development, and Global Operations
SINGAPORE and SAN DIEGO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Helport AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPAI#NASDAQ">HPAI</a>) ("Helport AI" or the "Company"), an AI technology company serving enterprise clients with intelligent customer communication software, services, and solutions, today announced the appointment of Amy Fong as President and as a director to its board of directors (the "Board"), effective January 1, 2025. Following the appointment of Ms. Fong, the Board will be comprised of 5 directors, 3 of whom are independent.

Management

HPAI

Helport AI Appoints Amy Fong As President And Director, Effective January 1, 2025

Benchmark analyst Christopher Kuhn reiterates Forward Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) from Hold to Hold.

Reiteration

Analyst Ratings

FWRD

Benchmark Reiterates Hold on Forward Airto Hold

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the information technology sector.
<h3 class="wp-block-heading">Opera Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>)</h3>
<ul>
<li>Dividend Yield: 4.14%</li>
<li>TD Cowen analyst Lance Vitanza maintained a Buy rating and raised the price target from $25 to $28 on Oct. 30. This analyst has an accuracy rate of 78%.</li>
<li>B. Riley Securities analyst Lee Krowl reiterated a Buy rating and increased the price target from $24 to $25 on Oct. 30. This analyst has an accuracy rate of 84%.</li>
<li>Recent News: On Dec. 12, Opera declared upcoming cash dividend of 40 cent per share under its recurring dividend program.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"> latest OPRA news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="921" height="871" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083907/image-2-12.png" alt="" class="wp-image-721810" style="width:658px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083907/image-2-12.png 921w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083907/image-2-12-300x284.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083907/image-2-12-768x726.png 768w" sizes="(max-width: 921px) 100vw, 921px" /></a></figure>
<h3 class="wp-block-heading">Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>)</h3>
<ul>
<li>Dividend Yield: 3.23%</li>
<li>Cantor Fitzgerald analyst C J Muse reiterated a Neutral rating with a price target of $125 on Oct. 23. This analyst has an accuracy rate of 68%.</li>
<li>Wedbush analyst Matt Bryson reiterated an Outperform rating with a price target of $150 on Oct. 23. This analyst has an accuracy rate of 80%.</li>
<li>Recent News: On Oct. 22, the company reported first-quarter revenue of $2.17 billion, beating the consensus of $2.119 billion.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1">latest STX new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="853" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083923/image-32.png" alt="" class="wp-image-721811" style="width:651px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083923/image-32.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083923/image-32-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083923/image-32-768x722.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>)</h3>
<ul>
<li>Dividend Yield: 3.00%</li>
<li>Morgan Stanley analyst Erik Woodring maintained an Equal-Weight rating and increased the price target from $208 to $222 on Dec. 16. This analyst has an accuracy rate of 63%.</li>
<li>BMO Capital analyst Keith Bachman maintained a Market Perform rating and boosted the price target price target from $235 to $260 on Oct. 24. This analyst has an accuracy rate of 82%.</li>
<li>Recent News: GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) and IBM recently announced a settlement resolving all ongoing lawsuits between the two companies, including claims related to breach of contract, trade secrets, and intellectual property.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to l<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1">atest IBM new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="916" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083958/image-33.png" alt="" class="wp-image-721812" style="width:630px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083958/image-33.png 916w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083958/image-33-300x274.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07083958/image-33-768x703.png 768w" sizes="(max-width: 916px) 100vw, 916px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42839544/wells-fargo-gears-up-for-q4-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">Wells Fargo Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Price Target

OPRA

Wall Street's Most Accurate Analysts Give Their Take On 3 Tech Stocks Delivering High-Dividend Yields

Palantir Technologies Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) stock price surged 355% over <a href="https://www.benzinga.com/quote/PLTR/news">the past 12 months</a>, but the shine may be fading as technical indicators and high-profile moves signal potential turbulence ahead.
<h2 class="wp-block-heading">Cathie Conundrum?</h2>
On Monday, Cathie Wood's investment management firm, ARK Invest, <a href="https://www.benzinga.com/25/01/42835519/cathie-woods-monday-moves-dumps-15m-worth-of-hot-stock-palantir-loads-up-amazon-com">offloaded $15 million worth</a> of Palantir stock, totaling 196,728 shares across its flagship ETFs, including ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>).
While Wood remains a long-time supporter of tech disruptors, her pivot toward Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) underscores growing concerns about Palantir&#8217;s valuation. The sale follows <a href="https://www.benzinga.com/quote/PLTR/analyst-ratings">Morgan Stanley's recent downgrade</a> to &#8220;underweight,&#8221; slapping a $60 price target on the stock despite its astronomical gains.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42804969/bitcoins-bullish-run-cathie-woods-trades-and-elon-musks-dogecoin-influence-this-week-in-crypto">Bitcoin&#8217;s Bullish Run, Cathie Wood&#8217;s Trades, And Elon Musk&#8217;s Dogecoin Influence: This Week In Crypto</a>
<h2 class="wp-block-heading">Palantir Stock Charts Giving Mixed Signals</h2>
Palantir&#8217;s technical picture paints a tale of two trends. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="483" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07073129/Screenshot-2025-01-07-at-5.59.34-PM.png" alt="" class="wp-image-721685" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07073129/Screenshot-2025-01-07-at-5.59.34-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/07073129/Screenshot-2025-01-07-at-5.59.34-PM-300x231.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent010725&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
While the stock's 200-day simple moving average (SMA) at $37.69 screams bullish, shorter-term averages like the eight-day ($77.62) and 20-day ($76.28) SMAs suggest selling pressure. 
The moving average convergence/divergence (MACD) indicator, at a bullish 3.16, offers hope, but the RSI of 54.77 keeps sentiment lukewarm.
<h2 class="wp-block-heading">Market Overhang Or Opportunity?</h2>
Palantir's success in U.S. government contracts and the commercial sector bolsters its growth narrative, but analysts remain divided. Jim Cramer, host of CNBC's Mad Money, <a href="https://www.benzinga.com/markets/equities/25/01/42835613/jim-cramer-predicts-palantir-buying-surge-tonight-after-morgan-stanleys-underweight-rating-unless-another-analyst-starts-with-a-sell">hinted at adding Palantir stock </a>to his portfolio, offering a contrarian view against the bearish sentiment from Morgan Stanley.
Meanwhile, the stock's recent one-month dip of 4.97% signals caution among traders.
With a valuation as polarizing as its investor base, Palantir stands at a crossroads. Bulls point to long-term momentum and a 50-day SMA of $65.73 providing solid support, while bears focus on recent selling pressure and a frothy price tag.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/01/42806417/jim-cramer-works-sunday-brainstorm-on-buying-palantir-and-tesla-stock-calls-them-protective-intellectual-blankets">Jim Cramer Works &#8216;Sunday Brainstorm&#8217; On Buying Palantir And Tesla Stock, Calls Them &#8216;Protective Intellectual Blankets&#8217;</a></li>
</ul>
Image: Shutterstock

Technicals

Tech

AMZN

ARKK

ARKW

PLTR

Palantir Stock Rally Stalls As Cathie Wood's ARK Invest Sells $15M In Shares

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), the Danish pharmaceutical giant behind weight-loss drugs Wegovy and Saxenda, is facing scrutiny over its sponsorship deals <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42764490/us-employer-health-costs-to-rise-in-2025-fueled-by-weight-loss-report" rel="noreferrer noopener">with U.K. pharmacies</a>.
Critics argue these arrangements reveal troubling conflicts of interest and highlight gaps in regulating prescription drug advertising.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42811734/novo-nordisk-pushes-fda-to-exclude-compounding-for-its-early-generation-diabetes-drug" rel="noreferrer noopener">Novo Nordisk Pushes FDA To Exclude Compounding For Its Early-Generation Diabetes Drug</a>
Between 2021 and 2023, Novo Nordisk provided substantial funding to major pharmacy chains such as Boots and Lloyds as well as smaller online clinics.
The sponsorships, valued in the hundreds of thousands of pounds, funded advertising campaigns, pharmacist training and the creation of patient resources.
In return, pharmacies supplied Novo Nordisk with detailed reports on prescription numbers, advertising performance and patient demographics.
While Novo Nordisk insists these sponsorships adhered to industry standards, critics have raised concerns about the ethical implications of such financial ties.
The company's sponsorship practices also drew regulatory scrutiny.
In 2022, Novo Nordisk signed a $119,000 (95,000 pounds) deal with Boots to fund training and advertising for its weight-loss services.
Additional deals with other pharmacies provided free supplies and marketing materials.
However, in October 2024, the UK&#8217;s Prescription Medicines Code of Practice Authority (PMCPA) ruled that these arrangements violated industry codes, citing a lack of partnership independence and inadequate safeguards against incentivizing prescriptions.
Further issues emerged when Novo Nordisk funded online clinics such as the Slimming Clinic and WebMed pharmacy. Both were later found to have illegally promoted prescription-only weight-loss drugs, including Wegovy and Saxenda, on social media.
Posts by the clinics featured images of weight-loss injection pens and direct references to the drugs, violating UK advertising rules.
Novo Nordisk denied knowledge of the clinics' promotional practices and emphasized that its sponsorships were intended for patient education, not marketing.
A 2023 investigation by The Guardian <a href="https://www.theguardian.com/business/2025/jan/04/wegovy-maker-novo-nordisk-sponsored-british-pharmacies-in-pursuit-of-sales" target="_blank" rel="noreferrer noopener">found</a> that nearly 50 companies were reprimanded over similar breaches between January 2023 and September 2024.
In the new year, the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) urged the public to avoid purchasing weight-loss medicines without a prescription from unauthorized sources like beauty salons, social media platforms <a href="https://www.benzinga.com/markets/eurozone/25/01/42772200/dont-buy-weight-loss-medication-from-unauthorized-sources-uk-health-agency-warns-about-risks" target="_blank" rel="noreferrer noopener">or unverified websites</a>.
Price Action: NVO stock is down 1.01% at $84.17 during the premarket session at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42841672/stryker-to-buy-inari-medical-for-around-5-billion-to-bolster-position-in-segment-for-venous-thromboembolism" target="_blank" rel="noreferrer noopener">Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Biotech

Large Cap

Health Care

General

Novo Nordisk's Sponsorship Deals With UK Pharmacies Linked To Weight-Loss Drugs Raise Ethical Concerns

AMST

Amesite shares are trading lower after the company announced a $3.6 million public offering of 1.2 million units.

<a href="https://www.benzinga.com/news/24/12/42689559/mark-zuckerberg-talks-non-profit-achievements-while-displaying-a-1-2-million-patek-philippe-watch">Mark Zuckerberg</a>, the CEO of Meta (formerly Facebook), has built his share of virtual communities – but his latest venture is a little more offline.&nbsp;
On the Hawaiian island of Kauai, Zuck has spent $187 million amassing 1,600 acres of paradise. Officially, he calls it "Koʻolau Ranch." Unofficially, it's been nicknamed everything from a luxury retreat to an apocalypse bunker. Zuckerberg, however, insists the compound isn't as ominous as people think.
Don't Miss:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
In an interview with The Circuit w/ Emily Chang, highlighted by Surfer.com on Dec. 31, Zuckerberg addressed the elephant – or rather, the bunker – in the room. Chang jokingly asked, "You do have a bunker there. Is there something you know that we don't?" Zuckerberg laughed it off, responding, "No, I think that's just like a little shelter. It's a basement … It got blown out of proportion as if the whole ranch was some kind of doomsday bunker, which is just not true."
What he calls "a little shelter" might be an understatement to some. According to Hawaii News Now, the so-called "storage space" beneath his sprawling estate is about the size of an NBA court. Whether he's stashing canned goods or holiday decorations down there, that's a lot of room for "basic storage."
See Also: Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a>
The Grand Vision
Zuckerberg's Kauai project is <a href="https://www.benzinga.com/startups/24/08/40580553/mark-zuckerbergs-ai-obsession-is-8-billion-too-much-for-meta-to-handle">anything but modest</a>. Since 2014, he's acquired over 1,600 acres on the island, investing millions to create what's shaping up to be a self-sustaining, luxurious compound. Features include:
• Two massive mansions totaling 57,000 square feet.
• 30 bedrooms and 30 bathrooms – enough for the largest of guest lists.
• Treehouses connected by rope bridges, giving off a Swiss Family Robinson vibe (if Robinson had billions).
• Multiple pools, hot tubs and even a tennis court.
"A Little Shelter" That's Anything But
The compound's most intriguing feature is the underground "shelter." Here's what's known:
• A 5,000-square-foot bunker complete with living quarters, a mechanical room and an escape hatch.
• Connected to the main house via tunnels for easy access.
• Reinforced with a blast-resistant metal door filled with concrete.
Whether it's a hurricane shelter or a prepper's paradise, Zuckerberg's setup is built to last.
Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
Sustainability – or Survival?
The ranch is also designed to be self-sufficient. Zuckerberg has made it clear he's focusing on sustainability, not survivalism. His efforts reportedly include:
• A private water system for the compound.
• Cattle ranching for high-quality beef and agricultural self-reliance.
• Wildlife preservation and native plant restoration to minimize his environmental footprint.
Security and Secrecy
Of course, no tech billionaire's fortress is complete without a layer of mystery. The estate features:
• A 6-foot-high wall surrounding the property.
• Strict nondisclosure agreements for all workers and visitors.
• Private security patrols that reportedly monitor nearby beaches.
Controversy Among the Locals
As with any megaproject, there's been a backlash. Locals have raised concerns about the compound's size and impact on the community, despite Zuckerberg's assurances of environmental preservation.
Whether you see it as an eco-friendly haven or a <a href="https://www.benzinga.com/startups/24/03/37514075/billionaire-bunker-with-a-flaming-moat-and-drawbridge-how-billionaires-like-mark-zuckerberg-are-taki">billionaire's end-of-the-world insurance policy</a>, Mark Zuckerberg's Kauai compound is a testament to how far $187 million can go. For now, he seems content to keep wake-surfing and brushing off bunker jokes. But let's be honest – if anyone's prepared for the zombie apocalypse, it's probably Zuck.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/arrived-centennial">Jeff Bezos-Backed Arrived Homes Hits A Big Sale On Charlotte Property – Investors Earning A 34.7% Return</a></li>
</ul>

Real Estate

Mark Zuckerberg Spent $187 Million On 1,600 Acres of Hawaii Land To Build A Self-Sustaining Apocalypse Bunker – Calls It 'A Little Shelter'

PAYX

PYCR

Paychex To Acquire Paycor For $22.50 Per Share In Cash

SYRA

Syra Health shares are trading higher after the company announced it secured a workforce contract with the Washington D.C. government.

Safe &amp; Green Holdings Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) ("Safe &amp; Green Holdings" or the "Company"), a leading developer, designer, and fabricator of modular structures, today announced the appointment of Michael McLaren, MSc., MBA, as Chief Executive Officer and Director, effective immediately.
Mr. McLaren brings more than 30 years of leadership experience in the energy industry, including significant contributions to military and energy projects, field services, and mergers and acquisitions. He is the founder of several startups where he has led innovative energy solutions, manufacturing systems and is the developer and patent holder of an extensive catalog of energy and green technologies. Mr. McLaren earned a Master's Degree in Science and a Master's Degree in Business from the University of British Columbia.

SGBX

Safe & Green Holdings Corp. Appoints Michael McLaren As CEO, Effective Immediately

Piper Sandler analyst Charles Neivert maintains Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) with a Overweight and lowers the price target from $155 to $135.

Piper Sandler Maintains Overweight on Westlake, Lowers Price Target to $135

Two new programs incorporate OPTAVIA ASCEND products for easy nutrition, with or without medications, and provide strategies &amp; support to help with weight maintenance
High-protein products help preserve lean muscle mass during weight loss, addressing the accelerated muscle loss often associated with GLP-1 medications 1&#x2A;
Medifast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MED#NYSE">MED</a>), the health and wellness company known for its habit based and coach-guided lifestyle solution OPTAVIA, today announced OPTAVIA ASCEND — a new product line of high-protein, fiber-rich mini meals as well as a daily nutrient pack. These products are featured in two new science-backed nutrition plans designed for people on GLP-1 medications and those looking for help to keep weight off. The mini meals provide essential nutrients to promote muscle health, digestive health and bone health, and combined with the new plans and OPTAVIA's holistic offer, fill a critical gap in the weight management market.

Medifast Announces OPTAVIA ASCEND High-Protein, Fiber-Rich Mini Meals And Daily Nutrient Packs Aimed At Maintaining Lean Muscle Mass For GLP-1 Medication Users And Weight Management Support

Offerings

Amesite Prices Public Offering Of 1.2M Shares At $3.00 Each, Raising $3.6M; Closing Expected January 8, 2025

Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) maintains an upward stock trajectory this week after a power-packed start with the <a target="_blank" href="https://www.benzinga.com/tech/25/01/42838231/jensen-huang-unveils-3000-personal-ai-supercomputer-the-size-of-a-small-book-it-runs-the-entire-nvidia-ai-stack" rel="noreferrer noopener">Consumer Electronics Show (CES)</a>, Microsoft Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)&nbsp;eying&nbsp;an $80 billion investment in&nbsp;developing AI data centers for 2025, and Foxconn's <a target="_blank" href="https://www.benzinga.com/25/01/42813592/ai-chip-stocks-nvidia-broadcom-amd-taiwan-semi-micron-super-micro-surge-on-monday-whats-going-on" rel="noreferrer noopener">robust quarterly results</a>.
Chief&nbsp;Jensen Huang&nbsp;<a target="_blank" href="https://www.benzinga.com//node/42838231" rel="noreferrer noopener">announced the company's</a> $3,000 desktop-sized personal AI supercomputer, Project DIGITS, powered by the GB10 Grace Blackwell&nbsp;super chip, during his CES 2025 keynote.
Huang also presented&nbsp;the new&nbsp;RTX 5000 GPU&nbsp;series, laptops featuring the RTX 50-series, and the&nbsp;Grace Blackwell NVLink 72&nbsp;system.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42826372/intel-struggles-to-compete-with-amd-and-nvidia-in-data-centers-and-ai-chips" rel="noreferrer noopener">AMD and Nvidia Overtake Intel in Key Markets, Challenging Its Leadership</a>
Nvidia <a target="_blank" href="https://www.cnbc.com/2025/01/06/nvidia-releases-blackwell-gaming-chips-for-pcs-called-rtx-50-series-.html" rel="noreferrer noopener">told</a> CNBC that the high-end RTX 5090 chips will be able to run AI models and do computer graphics, including helping game makers integrate generative AI into their characters in games like PUBG: Battlegrounds.
The new processors will also be able to run large language models and image generation models from companies including&nbsp;Meta, Mistral, and Stability AI.
He also announced that&nbsp;Toyota&nbsp;Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) will use Nvidia&nbsp;Drive AGX Orin to enhance its <a target="_blank" href="https://www.benzinga.com/25/01/42836673/toyotas-next-gen-vehicles-to-use-nvidia-supercomputer-operating-system" rel="noreferrer noopener">automated driving capabilities</a>.
Nvidia forged a deal to provide driver-assistance chips and software for Toyota&nbsp;vehicles.
Nvidia expects its automotive vertical business to grow to ~$5 billion in fiscal 2026 from ~$4 billion in fiscal 2025.
Some of Nvidia&nbsp;Drive AGX clients include BYD Co (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>), Li Auto Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), Lucid Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>), Rivian Automotive, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>), Xiaomi Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACF#OTC">XIACF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>), ZEEKR Intelligent Technology Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZK#NYSE">ZK</a>).
At the event, Nvidia also flagged its alliance with&nbsp;Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)&nbsp;on innovating open-source Llama models, which Daniel Newman of&nbsp;The Futurum Group <a target="_blank" href="https://www.benzinga.com/news/global/25/01/42836461/nvidias-ces-2025-vision-sparks-mixed-reactions-ross-gerber-hails-incredible-things-to-come-while-analysts-debate-ai-and-autonomous-driving-ambitions" rel="noreferrer noopener">expects to outperform</a> OpenAI potentially.
Huang showcased physical AI tools to train robots, leveraging simulated environments that closely mimic the real world. These tools enabled higher automation in warehouses and factories and boosted a humanoid-robot market that the company said could be worth $38 billion in decades, the Wall Street Journal <a target="_blank" href="https://www.wsj.com/tech/ai/nvidia-ceo-pitches-robotics-cars-as-growth-areas-to-consumer-electronics-audience-68905f2d?mod=tech_lead_pos1" rel="noreferrer noopener">reports</a>.
Huang told the WSJ that the ChatGPT moment for general robotics is just around the corner.
Nvidia product director Justin Walker <a target="_blank" href="https://www.cnbc.com/2025/01/06/nvidia-releases-blackwell-gaming-chips-for-pcs-called-rtx-50-series-.html" rel="noreferrer noopener">told</a> CNBC that despite being an AI company and a gaming company, the gaming side still benefits tremendously from being an AI company.
Nvidia also announced its <a target="_blank" href="https://www.benzinga.com/government/regulations/25/01/42822625/big-techs-date-with-antitrust-alphabet-meta-amazon-brace-for-legal-showdowns-in-2025" rel="noreferrer noopener">Cosmos foundation models</a>, which generate photorealistic video to train robots and self-driving cars at a more affordable cost.
Cosmos will be available on an "open license," similar to Meta's&nbsp;Llama 3 language models. Huang expects Cosmos to do the same for robotics and industrial AI as Llama 3 has done for enterprise AI, Reuters reports.
Bank of America's Vivek Arya told Reuters that he will await possible upside from Nvidia's robotics by drawing [parallels with the metaverse and autonomous cars.
Price Action: NVDA stock is up 2.20% at $152.87 premarket at the last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/media/24/12/42721414/nvidia-targets-robotics-as-next-big-opportunity-amid-rising-ai-rivalry" target="_blank" rel="noreferrer noopener">Nvidia Targets Robotics as Next Big Opportunity Amid Rising AI Rivalry</a></li>
</ul>
Image via Shutterstock

Media

BYDDF

BYDDY

LCID

MSFT

NVDA

RIVN

XIACF

XIACY

Nvidia Highlights AI Chips Powering PUBG, Robotics 'ChatGPT Moment,' Automotive Expansion And More At CES Event

Piper Sandler analyst Charles Neivert maintains Ecolab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECL#NYSE">ECL</a>) with a Overweight and lowers the price target from $305 to $270.

Piper Sandler Maintains Overweight on Ecolab, Lowers Price Target to $270

Contracts

STRR

Star Equity Subsidiary, KBS Builders, Receives $3.2M Contract For A Multifamily Construction Project In Maine

Founder Group Secures $4.5M Letter Of Award For 9.99MW Floating Solar Farm Project In Malaysia; Construction Set To Complete By June 2025 Using Cutting-Edge FPV Technology To Maximize Energy Generation And Conserve Land

Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>) and Comcast (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) today announced the renewal of their comprehensive distribution agreements to continue delivering Paramount's leading portfolio of broadcast, entertainment, news and sports brands across Xfinity platforms.
The multi-year deals feature ongoing carriage of Paramount's networks, including CBS, BET, Comedy Central, MTV, Nickelodeon, Paramount Network and more. Comcast subscribers will also retain access to Paramount's popular streaming services across Paramount+, Pluto TV and BET+. Additionally, as part of the renewal, Comcast has the right to make Paramount+ with SHOWTIME available to qualifying Xfinity customers.

CMCSA

PARA

PARAA

Paramount Global And Comcast Renew Multi-Year Distribution Agreements To Deliver CBS, BET, Comedy Central, MTV, Nickelodeon, Paramount+ To Xfinity Platforms

Stifel Nicolaus analyst Daniel Arias maintained a Hold rating on Revvity (RVTY – Research Report) on November 25 and set a price target of $120.00....

Stifel Nicolaus Remains a Hold on Revvity (RVTY)

Janus Henderson Enterprise Fund Q3 2024 Commentary

Janus Henderson Mid Cap Growth Managed Account Q3 2024 Commentary

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AnaptysBio (ANAB – Research Report), Revvity (RVTY –...

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Revvity (RVTY) and McKesson (MCK)

BofA upgraded Revvity (RVTY) to Buy from Neutral with a $138 price target Having transformed its business over the last few years, the firm sees th...

Revvity upgraded to Buy from Neutral at BofA

Safe Biopharma: Revvity's Recurring Revenues And Diagnostics

Citi analyst Patrick B Donnelly maintained a Buy rating on Revvity (RVTY – Research Report) today and set a price target of $145.00. Patrick B Donn...

Revvity's Strategic Market Position and Anticipated Growth Drive Buy Rating

UBS says 'underweight the names with high China exposure'

Evercore ISI lowered the firm's price target on Revvity (RVTY) to $125 from $134 and keeps an Outperform rating on the shares. In the firm's 2025 o...

Revvity price target lowered to $125 from $134 at Evercore ISI

In a report released yesterday, Eve Burstein from Bernstein maintained a Buy rating on Revvity (RVTY – Research Report), with a price target of $14...

Bernstein Remains a Buy on Revvity (RVTY)

AAPL

ANAB

CNSWF

DLTR

EBAY

FLEX

FWONA

FWONB

FWONK

GDDY

ICUI

IFCZF

JAAA

JBBB

JMBS

JSMD

JSML

LPLA

LRCX

LULU

NXPI

OTIS

RKLIF

RVTY

SCHW

SSNC

VNLA

VTRS

Press Releases

Revvity To Hold Earnings Call on Monday, November 4, 2024

Revvity Highlights its Strong Progress on Sustainability and Workplace Culture in 2024 Impact Report

Revvity Introduces Transcribe AI: Revolutionizing Data Entry in Clinical Laboratories

Revvity Board Declares Quarterly Dividend

Revvity Announces Financial Results for the Third Quarter of 2024

Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation

Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference

Scale Biosciences and Revvity's BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells

Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK

Revvity to Present at J.P. Morgan Healthcare Conference

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Revvity

空売り

Revvity (NYSE:RVTY) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル